[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-inflammation":206},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,96,127,152,180],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100324933",false,"NCT03510442","Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions","Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease and Related Inflammatory Conditions","* INCLUSION CRITERIA:\n\nSubjects with known or suspected sJIA, AOSD or a similar inflammatory phenotype will provide informed consent and then be evaluated either in the outpatient or inpatient unit of the NIH Clinical Center. To be eligible for follow-up visits patients must meet the Inclusion Criteria, but not the Exclusion Criteria. Subjects determined to not have known or suspected sJIA or AOSD, or a related\n\ninflammatory phenotype, will not be followed.\n\nPatients with signs and symptoms of sJIA will be classified as outlined in #1, #2 and #3 below:\n\n1. Patients less than 16 years of age will be considered to have sJIA if they meet the ILAR criteria for sJIA.\n2. Patients 16 years of age and older will be considered to have sJIA if they have previously met ILAR criteria for sJIA.\n3. Family members of individuals included under items 1 and 2.\n4. Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will include both pediatric and adult patients and will not be pregnant.\n\nPatients with signs and symptoms of AOSD will be classified as outlined in #1, #2 and #3 below:\n\n1. Patients 16 years of age and older will be considered to have AOSD if they meet the Yamaguchi criteria for AOSD (including a negative ANA and RF).\n2. Patients may be considered to have a diagnosis of AOSD if they met criteria for diagnosis in the past but do not still have present evidence of disease.\n3. Family members of individuals included under items 1 and 2.\n4. Controls for clinical, cellular, molecular, and biochemical assays, and genetic evaluation will be enrolled. Individuals who undergo phlebotomy specifically to provide a control specimen will include both pediatric and adult patients and will not be pregnant.\n\nPatients with suspected sJIA, AOSD or a related inflammatory condition, as indicated by the presence of episodic fever and\u002For arthritis, may also be included.\n\nEXCLUSION CRITERIA:\n\n1. In adults, inability to provide informed consent and unavailability of a legally authorized representative to provide surrogate consent. In the case of minors, unavailability of a parent or guardian.\n2. Presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.\n3. Unavailability, or inability to adhere with the schedule for follow-up visits.\n4. Pregnancy",true,"ALL","1 Day","100 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Background:\n\nInflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD). Their causes are unknown. Researchers want to learn more about these conditions. This includes genetic changes and environmental factors.\n\nObjective:\n\nTo study sJIA and AOSD in children and adults over time.\n\nEligibility:\n\nPeople with known or suspected sJIA, AOSD, or similar inflammatory condition\n\nDesign:\n\nParticipants will be screened with a phone call.\n\nParticipants will have 1 visit. It may be outpatient or they may be admitted to the clinic. The visit may last up to 5 days. Participants will have:\n\n* Medical history\n* Physical exam\n* Musculoskeletal exam\n* Questions about overall health and quality of life, disease activity, functional status, and cognitive ability.\n\nParticipants may also have:\n\n* Pictures taken of their skin, joints, or spine\n* Blood, urine, and stool tests\n* Scans or X-rays of joints with arthritis\n* Chest X-ray\n* Heart tests\n* Skin biopsy. The skin will be numbed. The top layers of a small area will be scraped off.\n\nParticipants who have a joint aspiration may provide a fluid sample. The joint will be prepared, then fluid is removed by needle. A corticosteroid may be injected.\n\nParticipants who have a bone marrow biopsy may provide sample cells.\n\nParticipants may be seen by NIH specialists.\n\nMembers of the participant s family and healthy volunteers may give blood or saliva samples for genetic testing.\n\nParticipants may repeat some study tests every 6 months.",[25,26,27,28],"Still's Disease, Adult-Onset","Systemic Inflammation","Arthritis","Autoinflammatory Syndrome",[30,31,27,32,33],"Inflammation","Fever","Sequencing","Natural History","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2018-05-21",{"date":42,"type":21},"2050-01-01",{"name":44,"class":45},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100643710","NCT07643558","Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients","SUPPORT-Study = Effects of a Dietary SUPPlementation With Omega3-fatty Acids\u002F Fish Oil and Progressive Resistence Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal, and Urological Cancer Patients","SUPPORT","Inclusion Criteria:\n\n* Patients with malignant tumors undergoing curative or palliative treatment, including breast, ovarian, esophageal, pancreatic, gastric, colon, rectal, and prostate cancer, across all UICC stages\n* Women and men aged 18 years or older\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Bone metastases or skeletal involvement associated with a high risk of fracture\n* Pregnant or breastfeeding women\n* Patients with psychiatric disorders that raise concerns regarding decision-making capacity or ability to provide informed consent\n* Participation in other exercise and\u002For nutritional intervention studies within the previous 3 months\n* Current use of fish oil supplements\n* Severe cardiovascular disease, NYHA class IV","18 Years",{"count":56,"type":21},288,"INTERVENTIONAL",[59],"NA","Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life.\n\nIn addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass.\n\nThe aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.",[62,63,64,65,66,26],"Cancer Cachexia","Omega 3","Resistance Training","Cancer","Muscle Wasting",[68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85],"Resistance training","Progressive resistance exercise","Exercise therapy","Supportive cancer care","Nutritional intervention","Protein-rich nutrition","Nutritional supplementation","Omega-3 fatty acids","Eicosapentaenoic acid (EPA)","Docosahexaenoic acid (DHA)","Fish oil supplementation","Physical performance","Quality of life","Fatigue","Appetite","Patient-reported outcomes","Randomized placebo-controlled trial","Cachexia risk","2026-06-08",{"date":88,"type":38},"2026-06-11",{"date":90,"type":38},"2026-01-01",{"date":92,"type":21},"2029-10",{"name":94,"class":95},"University of Erlangen-Nürnberg Medical School","OTHER",{"id":97,"slug":4,"hasResults":10,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":10,"sex":16,"minAge":54,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":57,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100579818","NCT06829238","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)","(MET-IH)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent.\n* Stated willingness to comply with all study procedures and availability for the study duration.\n* Aged 18 to 64 years old.\n* Weight of at least 110 lbs.\n* Body Mass Index (BMI) of 18.5-40. Enrollment of individuals with BMI \\>40, deemed in good health, may be considered with approval.\n* Willingness to receive Jynneos (MPOX) and Capvaxvie vaccines.\n* Ability to take oral medication and willingness to adhere to the metformin treatment regimen.\n* History of injection opioid, amphetamine, and\u002For cocaine use within the past 10 years (self-report).\n* Use of non-prescription opioid, amphetamine, and\u002For cocaine within the past 30 days (self-report).\n* Clinically confirmed urine drug screen for opioid, amphetamine, and\u002For cocaine within the past 30 days.\n* Serum CRP \\> 3 mg\u002FdL.\n* Glucose level between 70-180 mg\u002FdL (non-fasting).\n* Hemoglobin A1c (HbA1c) of 5.0-6.4%.\n* CD4 count \\> 200 cells\u002Fml.\n* If HIV-positive, HIV viral load \\\u003C 200 copies\u002Fml.\n* If HIV-positive, on anti-retroviral therapy (ART) for \\>12 months.\n\nExclusion Criteria:\n\n* Inability to give informed consent.\n* Refusal or inability to have blood drawn.\n* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, platelet disorder requiring precautions).\n* Pregnant or nursing individuals.\n* Diabetes mellitus.\n* History of severe renal impairment or eGFR \\\u003C60 mL\u002Fmin\u002F1.73m².\n* Creatinine clearance \\\u003C60 mL\u002Fmin.\n* History of liver disease.\n* ALT\u002FAST \\> 3× the upper limit of normal.\n* Total bilirubin \\>1.4 mg\u002FdL.\n* Albumin \\\u003C3.5 g\u002FdL.\n* Prothrombin \\>1.5× the upper limit of normal.\n* AUDIT-C score ≥8.\n* Hemoglobin \\\u003C9.0 g\u002FL.\n* Absolute neutrophil count \\\u003C1,000\u002FmL.\n* Platelet count \\\u003C100,000\u002FmL.\n* History of acute or chronic metabolic acidosis.\n* Serum bicarbonate \\\u003C22 mEq\u002FL.\n* Anion gap \\>10 mEq\u002FL.\n* Serum lactate \\>2.2 mmol\u002FL.\n* Serum vitamin B12 \\\u003C250 pg\u002FmL.\n* History of chronic diarrhea.\n* Current use of metformin or other diabetes medications.\n* History of myocardial infarction, endocarditis, stroke, heart failure, chronic obstructive pulmonary disease, or sepsis.\n* Use of medications such as furosemide, nifedipine, ranolazine, vandetanib, or cimetidine (current or within the past 30 days).\n* Active hepatitis B infection.\n* Hepatitis C infection within 6 months of study entry; individuals with prior hepatitis C must be at least 6 months post-treatment with direct-acting antivirals.\n* Previous receipt of Jynneos or pneumococcal vaccine within the past two years (self-report).\n* Severe allergic reaction to metformin, Jynneos, or Capvaxvie (self-report). Blood donations exceeding 450 mL in the 8 weeks prior to enrollment, accounting for study-related blood draws.\n* Any medical, psychiatric, social condition, or responsibility that, in the investigator's judgment, could interfere with study procedures.","64 Years",{"count":105,"type":21},100,[107],"PHASE4","This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.",[26,110,111,112],"Immune Dysregulation","Injection Drug Use","HIV",[114,115,116,117],"Metformin","Immune restoration","Vaccine response","People who inject drugs (PWID)","2026-04-17",{"date":120,"type":38},"2026-04-22",{"date":122,"type":38},"2025-04-07",{"date":124,"type":21},"2029-11-30",{"name":126,"class":95},"University of Alabama at Birmingham",{"id":128,"slug":4,"hasResults":10,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":10,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":57,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":151},"100531469","NCT06200207","A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation","Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation","ATHENA","Inclusion Criteria:\n\n* Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg\u002FL) at screening (visit 1)\n* Disease specific - cardiovascular:\n* N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg\u002FmL) (375 pg\u002FmL for participants with atrial fibrillation\u002Fflutter) at screening\n* Diagnosis of heart failure (New York heart association (NYHA) Class II-III)\n* Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation)\n* Structural heart disease and\u002For functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:\n\n  1. Left atrial (LA) volume index greater than 34 milliliter per square meter (mL\u002Fm\\^2)\n  2. LA diameter greater than or equal to 3.8 centimeter (cm)\n  3. LA length greater than or equal to 5.0 cm\n  4. LA area greater than or equal to 20 square centimeter (cm\\^2)\n  5. LA volume greater than or equal to 55 milliliter (mL)\n  6. Intraventricular septal thickness greater than or equal to 1.1 cm\n  7. Posterior wall thickness greater than or equal to 1.1 cm\n  8. LV mass index greater than or equal to 115 gram per square meter (g\u002Fm\\^2) in men or greater than or equal to 95 g\u002Fm\\^2 in women\n\n  h) E\u002Fe' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeter per second (cm\u002Fs)\n* No heart failure hospitalisations or urgent heart failure visits between screening and randomisation\n* Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres\n* Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening\n\nExclusion Criteria:\n\n* Medical conditions - cardiovascular:\n* Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1)\n* Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs\n* Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1)\n* Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1)\n* Planned cardiac device or atrial flutter\u002Fatrial fibrillation ablation procedure known during the screening period (visit 1)\n* Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2)\n* Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease\n* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD)\n* Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism)\n* Medical conditions - infections\u002Fimmunosuppression:\n* Clinical evidence of, or suspicion of, active infection at the discretion of the investigator",{"count":135,"type":21},680,[137],"PHASE3","The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.",[140,26],"Heart Failure","2026-04-04",{"date":143,"type":38},"2026-04-07",{"date":145,"type":38},"2024-04-01",{"date":147,"type":21},"2027-01-08",{"name":149,"class":150},"Novo Nordisk A\u002FS","INDUSTRY",240,{"id":153,"slug":4,"hasResults":10,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":15,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":46},"100609697","NCT07217951","Assessing the Feasibility of Multi-modal Biosensing for Monitoring Mobility and Cognition in Older Adults","Inclusion Criteria:\n\n1. Aged 65 or older\n2. Expressed willingness to participate.\n3. Able to give written informed consent\n4. Able to operate a smartphone and complete surveys\n\nExclusion Criteria:\n\n1. Reliance on assistive walking devices\n2. Inability to operate a smartphone\n3. Unable to complete surveys\n4. Unable to give written informed consent\n5. Younger than 65 years old\n6. Known skin allergies to kinesiology tape (KT tape)","65 Years",{"count":159,"type":21},20,"Current health devices often overlook older users, who may face both health challenges and technology barriers. We are investigating the feasibility of wearable sensors to track posture, heart rate, and breathing, alongside a microneedle patch that collect body fluids to measure stress and inflammation markers. By combining this data, we aim to create an easy to use system that supports personalized, at home health monitoring for older adults.",[162,26,163],"Chronic Stress","Mobility and Independence",[165,166,167,168,169],"wearable sensors","older adults","aging","mobility","inflammation","NOT_YET_RECRUITING","2025-10-16",{"date":173,"type":38},"2025-10-20",{"date":175,"type":21},"2025-12",{"date":177,"type":21},"2028-09",{"name":179,"class":95},"Tufts University",{"id":181,"slug":4,"hasResults":10,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":15,"sex":16,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":57,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":46},"100521628","NCT06072066","Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","The Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","Inclusion Criteria:\n\n* Males and females 30 to 70 years of age\n* The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)\n* High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg\u002FL\n\nExclusion Criteria:\n\n* The presence of severe rosacea as noted by the investigator global assessment.\n* Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.\n* Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment\n* Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.\n* Those who are unwilling to keep their facial regimen the same throughout the study.\n* Individuals who have been on an oral antibiotic within the previous one month.\n* Individuals who are pregnant or breastfeeding.\n* Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.\n* Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.\n* Use of isotretinoin within the three months prior to enrollment.\n* Individuals on finasteride or dutasteride\n* Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.","30 Years","70 Years",{"count":189,"type":21},24,[59],"The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.",[193,26],"Rosacea",[193,195,196],"L-Histidine","Antioxidants","2024-08-26",{"date":199,"type":38},"2024-08-27",{"date":201,"type":38},"2023-11-22",{"date":203,"type":21},"2024-12-31",{"name":205,"class":150},"Integrative Skin Science and Research",""]